Cetuximab

• Description:

  Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity[1].

• Product Name Alternative:

  C225; IMC-C225

• UNSPSC:

  12352203

• Target:

  EGFR; Radionuclide-Drug Conjugates (RDCs)

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Anti-EGFR_Neutralizing_Antibody.html

• Purity:

  99.70

• Solubility:

  H2O

• Smiles:

  [Cetuximab]

• Molecular Weight:

  (145.54 kDa)

• References & Citations:

  [1]Goldstein NI, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1 (11) :1311-8.|[2]Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.|[3]Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59 (8) :1935-40.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Store at 4°C for 2 years, do not freeze

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Launched

• Isoform:

  EGFR/ErbB1/HER1; RDC Antibody

• CAS Number:

  [205923-56-4]